ResearcherLeiden University Medical CenterNo recent work listed
Isaura S. Ibrahim
Matched on ORCID iD 0000-0002-6457-1502; OpenAlex author ID A5038154655. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 38
2016: 2 papers · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: 2 papers
Papers 7
- Longitudinal changes of serum protein N-Glycan levels for earlier detection of pancreatic cancer in high-risk individuals. Co-author DOI 10.1016/j.pan.2022.03.021↗
- Pancreatic Cancer Surveillance in Carriers of a Germline CDKN2A Pathogenic Variant: Yield and Outcomes of a 20-Year Prospective Follow-Up. Co-author DOI 10.1200/jco.22.00194↗
- Dilatation of the main pancreatic duct as first manifestation of small pancreatic ductal adenocarcinomas detected in a hereditary pancreatic cancer surveillanc… Co-author DOI 10.1016/j.hpb.2019.02.013↗
- High Growth Rate of Pancreatic Ductal Adenocarcinoma in CDKN2A-p16-Leiden Mutation Carriers. Co-author DOI 10.1158/1940-6207.capr-18-0035↗
- Dilemmas in the management of screen-detected lesions in patients at high risk for pancreatic cancer. Co-author DOI 10.1007/s10689-016-9915-3↗
- Refinement of screening for familial pancreatic cancer. Co-author DOI 10.1136/gutjnl-2015-311098↗
- Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers. First author DOI 10.1200/jco.2015.64.0730↗
Closest collaborators
The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Bert A. Bonsing · 7 shared papers, 2016–2022 · strength 0.57
- Paper Pancreatic Cancer Surveillance in Carriers of a Germline CDKN2A Pathogenic Variant: Yield and Outcomes of a 20-Year Pro… DOI 10.1200/jco.22.00194↗
- Paper Longitudinal changes of serum protein N-Glycan levels for earlier detection of pancreatic cancer in high-risk individua… DOI 10.1016/j.pan.2022.03.021↗
- Paper Dilatation of the main pancreatic duct as first manifestation of small pancreatic ductal adenocarcinomas detected in a … DOI 10.1016/j.hpb.2019.02.013↗
- Hans F. A. Vasen · 7 shared papers, 2016–2022 · strength 0.57
- Paper Pancreatic Cancer Surveillance in Carriers of a Germline CDKN2A Pathogenic Variant: Yield and Outcomes of a 20-Year Pro… DOI 10.1200/jco.22.00194↗
- Paper Longitudinal changes of serum protein N-Glycan levels for earlier detection of pancreatic cancer in high-risk individua… DOI 10.1016/j.pan.2022.03.021↗
- Paper Dilatation of the main pancreatic duct as first manifestation of small pancreatic ductal adenocarcinomas detected in a … DOI 10.1016/j.hpb.2019.02.013↗
- Martin N.J.M. Wasser · 6 shared papers, 2016–2022 · strength 0.45
- Paper Pancreatic Cancer Surveillance in Carriers of a Germline CDKN2A Pathogenic Variant: Yield and Outcomes of a 20-Year Pro… DOI 10.1200/jco.22.00194↗
- Paper Dilatation of the main pancreatic duct as first manifestation of small pancreatic ductal adenocarcinomas detected in a … DOI 10.1016/j.hpb.2019.02.013↗
- Paper Dilemmas in the management of screen-detected lesions in patients at high risk for pancreatic cancer. DOI 10.1007/s10689-016-9915-3↗
- Hans Morreau · 4 shared papers, 2016–2022 · strength 0.30
- Paper Pancreatic Cancer Surveillance in Carriers of a Germline CDKN2A Pathogenic Variant: Yield and Outcomes of a 20-Year Pro… DOI 10.1200/jco.22.00194↗
- Paper Dilemmas in the management of screen-detected lesions in patients at high risk for pancreatic cancer. DOI 10.1007/s10689-016-9915-3↗
- Paper High Growth Rate of Pancreatic Ductal Adenocarcinoma in CDKN2A-p16-Leiden Mutation Carriers. DOI 10.1158/1940-6207.capr-18-0035↗
- Monique Esther van Leerdam · 2 shared papers, 2022 · strength 0.25
- Paper Pancreatic Cancer Surveillance in Carriers of a Germline CDKN2A Pathogenic Variant: Yield and Outcomes of a 20-Year Pro… DOI 10.1200/jco.22.00194↗
- Paper Longitudinal changes of serum protein N-Glycan levels for earlier detection of pancreatic cancer in high-risk individua… DOI 10.1016/j.pan.2022.03.021↗
- Derk C.F. Klatte · 2 shared papers, 2022 · strength 0.25
- Paper Pancreatic Cancer Surveillance in Carriers of a Germline CDKN2A Pathogenic Variant: Yield and Outcomes of a 20-Year Pro… DOI 10.1200/jco.22.00194↗
- Paper Longitudinal changes of serum protein N-Glycan levels for earlier detection of pancreatic cancer in high-risk individua… DOI 10.1016/j.pan.2022.03.021↗
- Bas Boekestijn · 2 shared papers, 2019–2022 · strength 0.23
- Paper Pancreatic Cancer Surveillance in Carriers of a Germline CDKN2A Pathogenic Variant: Yield and Outcomes of a 20-Year Pro… DOI 10.1200/jco.22.00194↗
- Paper Dilatation of the main pancreatic duct as first manifestation of small pancreatic ductal adenocarcinomas detected in a … DOI 10.1016/j.hpb.2019.02.013↗
- Wouter H. de Vos tot Nederveen Cappel · 3 shared papers, 2016–2019 · strength 0.21
- Paper Dilatation of the main pancreatic duct as first manifestation of small pancreatic ductal adenocarcinomas detected in a … DOI 10.1016/j.hpb.2019.02.013↗
- Paper High Growth Rate of Pancreatic Ductal Adenocarcinoma in CDKN2A-p16-Leiden Mutation Carriers. DOI 10.1158/1940-6207.capr-18-0035↗
- Paper Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Stud… DOI 10.1200/jco.2015.64.0730↗
- Rob A.E.M. Tollenaar · 2 shared papers, 2018–2022 · strength 0.19
- Thomas P. Potjer · 2 shared papers, 2016–2022 · strength 0.17
- Paper Pancreatic Cancer Surveillance in Carriers of a Germline CDKN2A Pathogenic Variant: Yield and Outcomes of a 20-Year Pro… DOI 10.1200/jco.22.00194↗
- Paper Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Stud… DOI 10.1200/jco.2015.64.0730↗
- Jeanin Elise van Hooft · 1 shared paper, 2022 · strength 0.13
- J. Sven D. Mieog · 1 shared paper, 2022 · strength 0.13
- Brechtje D.M. Koopmann · 1 shared paper, 2022 · strength 0.12
- Iris J. M. Levink · 1 shared paper, 2022 · strength 0.12
- Manfred Wuhrer · 1 shared paper, 2022 · strength 0.12
- Gerda C. M. Vreeker · 1 shared paper, 2022 · strength 0.12
- Randa G. Hanna-Sawires · 1 shared paper, 2022 · strength 0.12
- Kasper A. Overbeek · 1 shared paper, 2022 · strength 0.12
- Marco J. Bruno · 1 shared paper, 2022 · strength 0.12
- Yuri E. M. van der Burgt · 1 shared paper, 2022 · strength 0.12
- Djuna L. Cahen · 1 shared paper, 2022 · strength 0.12
- Wilma E. Mesker · 1 shared paper, 2022 · strength 0.12
- Gwenny Manel Fuhler · 1 shared paper, 2022 · strength 0.12
- Evelina Mocci · 2 shared papers, 2016 · strength 0.08
- Detlef Klaus Bartsch · 2 shared papers, 2016 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.